DOCSLIB.ORG

A Drug Quality System for the 21St Century April 22-24, 2003 Listing of Attendees

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Drug Quality System for the 21St Century April 22-24, 2003 Listing of Attendees A Drug Quality System for the 21st Century April 22-24, 2003 Listing of Attendees Abboud, Leila Armstrong, Ronald Blumberg, Eric Washington, DC Boehringer Ingelheim Pharm Food and Drug Administration Ridgefield, CT Rockville, MD Abrams, Shelley Eli Lilly and Company Bailey, John Blumenschein, Frederick Indianapolis, IN CTFA Food and Drug Administration Washington, DC Rockville, MD Agarwal, Rajiv Food and Drug Administration Bangert, Fred Blumenstein, Jeffrey Rockville, MD Synthon Pharmaceutials Pfizer, Inc. Chapel Hill, NC Groton, CT Agharkar, Shreeram Aventis Pharmaceuticals Co. Barreto, Dan Boehm, Garth Bridgewater, NJ Janssen Pharmaceutica Alpharma Beerse, Belgium Elizabeth, NJ Aikman, Mark Osmotica USA Barrett, Jennifer Boos, Lawrence Wilmington, NC Barr Laboratories President & CEO Pomona, NY Fort Worth, TX Ajac, Akin-Remi Ivax Pharmaceuticals, Inc. Batliner, Stephanie Bowen, Keith Miami, FL Phoenix Scientific, Inc. Centocor, Inc. Saint Joseph, MO Malvern, PA Akintonde, Daniel Hoffmann-La Roche, Inc. Baum, Robert Bowers, Lee Nutley, NJ Pfizer, Inc. Food and Drug Administration Groton, CT Baltimore, MD Alasandro, Mark Merck & Co., Inc. Beckerman, Peter Boyko, Jean West Point, PA Food and Drug Administration Purdue Pharma, LP Rockville, MD Ardsley, NY Alexander, Diane Food and Drug Administration Beels, Christopher Brame, Will Rockville, MD GlaxoSmithKline Aventis Pasteur Stevenage, United Kingdom Marcy l'Etoile, France Allen, Jay Stelex-TVG Beltran, Philippe Brochu, William Bensalem, PA Sanofi-Synthelabo Mylan Technologies, Inc. Malvern, PA St Albans, VT Allen, Susan Food and Drug Administration Bensley, Dennis Brock, Chris Rockville, MD Food and Drug Administration PPD Rockville, MD Wilmington, NC Allera, Edward John Buchanan Ingersoll Benson, Sheri Buehler, Gary Washington, DC Monsanto Food and Drug Administration Saint Louis, MO Rockville, MD Angelo, Michael Merck & Co., Inc. Berg, Mats Buhay, Nicholas Whitehouse Station, NJ Ernst & Young Food and Drug Administration Malmoe, Sweden Rockville, MD Anisko, Joseph Alkermes, Inc. Berger, Mitchell Bunpei, Matoba Cambridge, MA Thompson Publishing Group IBM Business Consulting Svcs Washington, DC Tokyo, Japan Anliker, Sally Eli Lilly and Company Berglund, Richard Burgenson, Al Indianapolis, IN Eli Lilly and Company Cambrex Bio Science Indianapolis, IN Walkersville, MD Anquez, Christelle Food and Drug Administration Bergt, Gregory Burlington, Bruce Rockville, MD Pennfield Animal Health Wyeth Pharmaceuticals Omaha, NE St. Davids, PA Arakangas, John Aramark AB Bird, Bruce Burtis, Mary Taylor Mariefred, Sweden Pfizer, Inc. Wyeth New York, NY Andover, MA Brought to you by: Food and Drug Administration and the Product Quality Research Institute Page 1 of 11 A Drug Quality System for the 21st Century April 22-24, 2003 Listing of Attendees Butler, Roger Chin, Tom DalPan, Gerald Eli Lilly Food and Drug Administration Food and Drug Administration Greenfield, IN Rockville, MD Rockville, MD Byers, James Chiu, Yuan-yuan Danford, Christopher Eli Lilly Food and Drug Administration Alcon Laboratories, Inc. Indianapolis, IN Rockville, MD Fort Worth, TX Byrn, Stephen Christian, Jorge Dansereau, France Purdue University Food and Drug Administration Health Canada Lafayette, IN Rockville, MD Ottawa, ON Canada Cannon, Laura Chudasama, Mahesh Dave, Pankaj Barr Laboratories, Inc. TEVA Pharmaceuticals USA Geneva Pharmaceuticals Cincinnati, OH Fairfield, PA Dayton, NJ Cantor, Jennifer Clark, Jon Davis, Colin 3M Pharmaceuticals Food and Drug Administration Pfizer, Inc. Saint Paul, MN Rockville, MD Kalamazoo, MI Caphart, Monica Claycamp, Gregg Dayman-Rutkus, Kim Food and Drug Administration Food and Drug Administration Health Canada Rockville, MD Rockville, MD Ottawa, ON Canada Carr, Paul Cobbs, Lindsay De, Swapan Shotwell and Carr, Inc. Food and Drug Administration Food and Drug Administration Flower Mound, TX Rockville, MD Rockville, MD Carroll, Michael Cohen, James DeMarco, Robert Hoffmann LaRoche Inc. Food and Drug Administration Wyeth BioPharma Nutley, NJ Rockville, MD Andover, MA Casey, Dennis Colborn, Alan DeVecchi, Franco Pfizer, Inc. GlaxoSmithKline VPCI, Inc. Groton, CT Zebulon, NC West Bloomfield, MI Chan, Tony Cole, Elaine DeWitt, Janet Guidant Corporation Food and Drug Administration Abbott Labs Temecula, CA Rockville, MD North Chicago, IL Chan, Yeung Collinsworth, Norma Diaz, Raul Bristol-Myers Squibb Co. GlaxoSmithKline Merck & Co., Inc. New Brunswick, NJ Durham, NC West Point, PA Chang, Karen Concavage, Debby Dietrick, John Alza Corporation AstraZeneca Pharmaceuticals LP Food and Drug Administration Mountain View, CA Westborough, MA Rockville, MD Charity, Anthony Cook, Jonathan Doleski, David Food and Drug Administration Food and Drug Administration Food and Drug Administration Rockville, MD Rockville, MD Rockville, MD Chen, Xiao-Hong Cooney, Peter Dove, Andrew Food and Drug Administration Food and Drug Administration The Pink Sheet Rockville, MD Rockville, MD Chevy Chase, MD Chermak, Todd Cordts, Jerome Doyle, Kevin Abbott Laboratories Food and Drug Administration Centocor Abbott Park, IL Rockville, MD Malvern, PA Chesney, David Crandell, Adela Drumm, Patrick KMI/PAREXEL ORGANICS/LaGrange, Inc. Novartis Pharmaceuticals Waltham, MA Northbrook, IL East Hanover, NJ Chiapperino, Dominic Crispin, Thomas D'sa, Albinus Food and Drug Administration Bayer AG Healthcare Group Food and Drug Administration Rockville, MD Leverkusen, Germany Rockville, MD Brought to you by: Food and Drug Administration and the Product Quality Research Institute Page 2 of 11 A Drug Quality System for the 21st Century April 22-24, 2003 Listing of Attendees Duffy, Eric Ferguson, Shirnette George, Mathew Food and Drug Administration Food and Drug Administration Pfizer, Inc. Rockville, MD Rockville, MD Brooklyn, NY Duple, Linda Finkbohner, John Ghani, Sultan Bimeda, Inc. Food and Drug Administration Health Canada Lehigh, IA Rockville, MD Ottawa, ON Canada Ealer, Norbert Fischer, Gerd Giertych, Amy AstraZeneca Pharmaceuticals Aventis Pharma Baxter Healthcare Corp. Wilmington, DE Frankfurt, Germany Round Lake, IL Edge Azuara, Kathy Folestad, Staffan Gilbert, Alicia Baxter Healthcare Corp. Astrazeneca Pharmaceuticals Human Genome Sciences, Inc. Westlake Village, CA Molndal, Sweden Rockville, MD Egan, William Foster, Todd Giorgetti, Michael Food and Drug Administration Pfizer, Inc. Alkermes Rockville, MD Kalamazoo, MI Cambridge, MA Ellsworth, Douglas Franklin, Craig Goldsmith, John Food and Drug Administration Salmedix Food and Drug Administration Parsippany, NJ San Diego, CA Rockville, MD Erario, Al Frederiksen, Linda Gomez, Ralph Dey, L.P. H. Lundbeck A/S Hoffmann-La Roche, Inc. Napa, CA Valby, Denmark Nutley, NJ Erlich, Ronald Friedman, Richard Good, Nancy JJPRD, LLC Food and Drug Administration Aventis Behring Raritan, NJ Rockville, MD King of Prussia, PA Evans O'Connor, Linda Fry, Edmund Gore, Ashok IVAX Pharmaceuticals Ivax Corporation Spectrum Pharmaceuticals Northvale, NJ Miami, FL Irvine, CA Eyraud, John Gaddy, Herschel Graeff, Brian Eastern Research Group, Inc. Herschel J. Gaddy & Associates AstraZeneca Lexington, MA Saint Joseph, MO Westborough, MA Fabian, Arthur Ganey, Michael Gray, Stephanie SST Corporation Pfizer, Inc. GlaxoSmithKline Clifton, NJ Groton, CT Research Triangle Park, NC Fahmy, Raafat Gantt, Sylvia Grazal, John Food and Drug Administration PQRI AstraZeneca Pharmaceuticals Rockville, MD Arlington, VA Wilmington, DE Fain, Kevin Gardine, Thomas Gregory, Norman Food and Drug Administration Food and Drug Administration Food and Drug Administration Rockville, MD Philadelphia, PA Rockville, MD Falk, Arthur Gavini, Muralidhara Grieve, Steven Elan Pharmaceutical Mgmt. Food and Drug Administration Pfizer, Inc. Morristown, NJ Rockville, MD Kalamazoo, MI Famulare, Joseph Gedz, Taras Grooms, Paul Food and Drug Administration Health Canada Baxter Healthcare Corporation Rockville, MD Ottawa, ON Canada Round Lake, IL Famulare, Joseph Gelwicks, Jeffrey Gross, Michael Food and Drug Administration Eli Lilly and Company Aventis Behring Rockville, MD Indianapolis, IN King of Prussia, PA Fazzari, Frank George, J. Glenn Guazzaroni, Maria Phoenix Regulatory Associates QRC Associates, LLC Pfizer, Inc. Sterling, VA Bedminster, NJ Morris Plains, NJ Brought to you by: Food and Drug Administration and the Product Quality Research Institute Page 3 of 11 A Drug Quality System for the 21st Century April 22-24, 2003 Listing of Attendees Guinty, William Hawley, Leslie Horowitz, David Aventis Pfizer, Inc. Food and Drug Administration Bridgewater, NJ Kalamazoo, MI Rockville, MD Guito, Kenneth Hayes, Denise Howe, Greg Aventis Pasteur, Inc. Pfizer, Inc. Schering Plough Animal Health Swiftwater, PA New York, NY Union, NJ Gulbinski, Donna Hayes, Mark Hsieh, Li-Shan Merck & Co., Inc. Genzyme Corporation Food and Drug Administration West Point, PA Framingham, MA Rockville, MD Gump, Edwin Heleter, Chris Hughes, Martin Boehringer Ingelheim Pharm Wyeth BioPharma Fort Dodge Animal Health Ridgefield, CT Andover, MA Princeton, NJ Gupta, Patti Henrikson, Erik Hussain, Ajaz Genentech Food and Drug Administration Food and Drug Administration S San Francisco, CA Rockville, MD Rockville, MD Guyer, C. Greg Henry, Louise Huynh, Mai Merck & Co., Inc. Vertex Pharmaceuticals Food and Drug Administration West Point, PA Cambridge, MA Rockville, MD Guyer, C. Greg Hentschel, Norbert Incorvia, Gary Merck & Co., Inc. Boehringer-Ingelheim Monsanto West Point, PA Biberach/Riss, Germany Saint Louis, MO Haberkorn, Richard Hess, Maureen Irminger, Lowell Genzyme
Load more

Recommended publications
  • Fully Human Domain Antibody Therapeutics: the Best of Both Worlds
    Drug Discovery Fully Human Domain Antibody Therapeutics: The Best of Both Worlds By combining the therapeutic benefits of small molecule drugs with those of fully human antibodies, Domain Antibodies are expected to have strong therapeutic and commercial potential. By Robert Connelly at Domantis Robert Connelly is Chief Executive Officer of Domantis. He has over 22 years’ commercial experience of the life science sector, including that gained in the fields of diagnostics, drug discovery technologies and antibody therapeutics. Prior to joining Domantis, he was CEO of Veritas Pharmaceuticals (Los Angeles, USA), an in vivo imaging start-up company. He spent over five years with IGEN International, latterly as Senior Vice President and General Manager, Life Sciences, where he took part in the company’s IPO and financing rounds, raising $130 million. The first 11 years of his career were spent at Abbott Laboratories in sales, marketing and management positions. Domain Antibodies (dAbs) are the smallest functional variable regions of either the heavy (VH) or light (VL) binding units of antibodies. At Domantis, we are chains of human antibodies. Domantis scientists applying our proprietary know-how in dAbs to deliver have used the variable domains sequences of human human therapies that address large, unmet medical antibodies to create a series of large and highly needs in areas such as inflammation, cancer and functional libraries of fully human dAbs, with each autoimmune diseases. Three and a half years after library comprising at least 1010 different dAbs. The opening our laboratories, we have a dozen proprietary dAbs selected from these libraries are both specific therapeutic programmes underway, and an additional for their biological target and are well folded and eight therapeutic programmes with partners.
    [Show full text]
  • Power List 2018
    APRIL 2018 # 40 Editorial Upfront In My View Sitting Down With Stop and look at how far Preparing for the EU’s new What can algae teach us Sophie Kornowski-Bonnet, the industry has come data protection regulation about medicine design? Roche Partnering 09 10 – 11 20 – 21 50 – 51 100 Power List 2018 www.themedicinemaker.com Continuous Growth Fibra-Cel® disks—3-D growth matrix for perfusion and continuous processes Suspend your disbelief: > Less susceptible to shear forces, The three-dimensional Fibra-Cel matrix clogging, and fouling entraps anchorage dependent and > Ideal for secreted product and vaccine suspension cells—for optimized growth production conditions and increased yields. > Suitable for GMP production > For use in autoclavable, sterilize-in- place or BioBLU® Single-Use Vessels www.eppendorf.com/Fibra-Cel Fibra-Cel® is a registered trademark owned by Imerys Minerals California, Inc., USA and licensed to Eppendorf, Inc., USA. Eppendorf®, the Eppendorf Brand Design and BioBLU® are registered trademarks of Eppendorf AG, Germany. All rights reserved, including graphics and images. Copyright © 2018 by Eppendorf AG. tmm_epp_ad_210x266_2018_04.indd 1 28.03.18 13:34 Online this Month The Power List The 2018 Power List, starting on page 24 of this issue, features 100 of the most inspirational professionals involved in A Scientist Walks into a Bar... format to the public”. Generally, drug development. The list was compiled it involves scientists speaking on a based on reader nominations and And gives a presentation as part variety of topics, from medicine, to feedback from a judging panel – but any of Pint of Science, a global science neuroscience, to robotics and more, in list will always be subjective.
    [Show full text]
  • Eli Lilly and Company
    Merrimack College Merrimack ScholarWorks Honors Senior Capstone Projects Honors Program Spring 2021 Eli Lilly and Company Alyssa Ardai Follow this and additional works at: https://scholarworks.merrimack.edu/honors_capstones Part of the Business Commons Ardai 1 Written Assignment #4 Eli Lilly and Company Alyssa Ardai Bus 4402W: Strategic Analysis and Decision Making Professor Herrmann April 30, 2021 Ardai 2 Abstract Eli Lilly and Company is a pharmaceutical company that has the goal of creating new products. Eli Lilly’s products are seen in hospitals and pharmacies around the US, with the hopes of growing internationally. By having a large number of drugs in their pipeline, they can be a key player in improving multiple types of illnesses as well as help aid the aging population. The healthcare sector is always one that is high-performing. Ardai 3 Eli Lilly and Company is positioned as a pharmaceutical company, with the goal of creating high-quality medicine for every need or to take a preexisting medicine and make it better. For the past 140 years, they have been creating medicine for various causes, but are now focusing their efforts on antibody treatments for the COVID-19 pandemic, as well as different cancers and autoimmune diseases. Everything that the company does should follow its core values: integrity, excellence, and respect for people (Eli Lilly and Company - A). Eli Lilly is found in the US, Japan, Europe, and hopes to expand to the rest of the world soon. They are broken down into Endocrinology, Oncology, Immunology, Neuroscience, & Other. The company has increased revenues from $23,832.8 - $25,925.3, a consistent tax rate of 15%, expenses increasing $300k a year, accounts receivable, or a/r, decreasing as they pay less in patents and drugs go generic, consistent inventory of $120k - $140k, showing they do not keep a lot on hand, a weighted average cost of capital, or WACC, of 5.9% showing it does not hold a lot of debt, and a long term growth rate of 2.3%, showing a healthy but stable growth (Bloomberg LP, CapitalIQ 2021).
    [Show full text]
  • List of Section 13F Securities
    List of Section 13F Securities 1st Quarter FY 2004 Copyright (c) 2004 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2004, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2004. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by Section 13(f)(1) and Rule 13f-1 thereunder.
    [Show full text]
  • A Balanced Trade Context for HIV Patent Pool
    iMedPub Journals 2011 TRANSLATIONAL BIOMEDICINE Vol. 2 No. 1:3 This article is available from: http://www.transbiomedicine.com doi: 10:3823/420 A Balanced Trade Context for HIV Patent Pool Daniele Dionisio, M.D. Member, European Parliament Working Group on Innovation, Access to Medicines and Poverty- Related Diseases. Reference Advisor for “Drugs for the developing countries”, SIMIT (Italian Abstract Society for Infectious and Tropical Diseases). Former Director, Infectious Disease Division, Pistoia city Hospital (Italy). Background: Reluctance of the multinational pharmaceutical companies to join the Medicines Patent Pool plan for HIV drugs (antiretrovirals-ARVs) might undermine E-mail: [email protected] its desirable objective of scaling up long-term, extended access to novel, affordable and appropriate ARV formulations in resource-limited settings. Methods: This paper makes an analysis of conflicting issues and calls for a trade context facilitating a reverse of multinational drug manufacturers’ reluctance to join patent pool. To this aim, partnerships between multinational companies are urged first to make cutting edge brand fixed-dose combination (FDC) ARVs promptly avail- able, and secondly, to allow patent pool agreements to be negotiated immediately afterwards. This context rejects clauses that exclude middle-income countries from sharing in the patent pool. Expected results: The suggested trade context can help speed up the partici- pation of originator pharmaceutical companies in the Medicines Patent Pool, while allowing them to maintain competitiveness, take advantage of incoming joint ven- ture opportunities and circumvent the need for additional incentives. This context potentially tackles in an appropriate way the directions of evolution in emerging markets, while bringing benefits to resource-limited populations, multinational drug corporations and manufacturers from middle-income countries.
    [Show full text]
  • Emergency Use Authorization (EUA)
    March 2, 2021 Eli Lilly and Company Attention: Christine Phillips, PhD, RAC Advisor Global Regulatory Affairs - US Lilly Corporate Center Drop Code 2543 Indianapolis, IN 46285 RE: Emergency Use Authorization 090 Dear Ms. Phillips: On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes coronavirus disease 2019 (COVID-19).1 On the basis of such determination, the Secretary of HHS on March 27, 2020, declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3), subject to terms of any authorization issued under that section.2 On November 9, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for emergency use of bamlanivimab for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab is a neutralizing IgG1 monoclonal antibody that binds to the receptor binding domain of the spike protein of SARS-CoV-2. It is an investigational drug and is not currently approved for any indication.
    [Show full text]
  • 2010 Annual Report and Proxy Statement
    Getting There Eli Lilly and Company 2010 Annual Report Notice of 2011 Annual Meeting Proxy Statement Getting There The Lilly Promise The path to Lilly’s future is a pipeline, and a bridge. Our Mission Lilly makes medicines that help people live longer, The future of our company depends on bringing to healthier, more active lives. patients innovative medicines that address unmet medical needs. We have a robust pipeline of promising molecules. Our Values To reach its future potential, Lilly must first bridge a period Integrity | Excellence | Respect for People we call “Years YZ” when we face a series of major patent We promise to operate our business with absolute expirations—including expiration of the U.S. patent for integrity and earn the trust of all, set the highest standards for our performance and for the performance Zyprexa® in late 2011. of our products, and demonstrate caring and respect We have been preparing for YZ in a number of ways: for all those who share in our mission and are touched Achieving volume-driven revenue growth, along with cost by our work. savings, to deliver consistently solid earnings based on our currently marketed products. Building growth engines—in Our Vision Japan, in key emerging markets, and in our animal health We will make a significant contribution to humanity by improving global health in the 21st century. Starting business—that can deliver new revenues through the YZ with the work of our scientists, we will place improved period. And aggressively pursuing business-development outcomes for individual patients at the center of what opportunities that strengthen our financial and commercial we do.
    [Show full text]
  • Welcome to the CMC Strategy Forum Prior Knowledge: Learning from Our Successes and Failures to Improve Product Development and Manufacturing
    Welcome to the CMC Strategy Forum Prior Knowledge: Learning from Our Successes and Failures to Improve Product Development and Manufacturing We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The meetings focus on relevant CMC issues throughout the lifecycle of a product and thereby foster collaborative technical and regulatory interactions. The Forum strives to share information with the regulatory agencies to assist them in merging good scientific and regulatory practices. Outcomes of the Forum meetings are published in an appropriate peer-reviewed journal. Each meeting will focus on a CMC related issue such as product characterization, comparability, specifications, etc. The format of each meeting will consist of case studies and presentations by industry and/or regulatory experts to introduce the topic and the key issues of concern. Workshop sessions, which consist of panel discussions and Q&A, will then be conducted to allow for additional discussion on the technical and regulatory details of the topics. It is envisioned that the final outcome of the workshop discussions will be the development of a document to be submitted to the appropriate Regulatory Agency designees for their consideration in developing and/or clarifying good regulatory practice guidelines for biotechnology derived products. The success of the CMC Strategy Forum will depend on your active participation in discussing and raising issues pertaining to development of biologics. We encourage you to participate wholeheartedly in the workshops that have been designed to stimulate exchange of ideas and information.
    [Show full text]
  • The Path Less Costly
    COMMENtaRY CASE STUDY The path less costly Brady Huggett When faced with a competitive threat, two companies took diametrically opposite approaches. Both were ultimately successful, but Genzyme’s decision proved to be the cleaner and cheaper option. s the world’s leader in developing enzyme-replacement drugs, and Novartis of Basel. Houston-based Tanox was founded in 1986 to AGenzyme has always understood the importance of first to market. In focus on anti-IgE antibodies and by 1989 was looking for a clinical 1991, the company obtained approval for Ceredase (alglucerase injection), development partner; it sent samples of its candidate to both Genentech an enzyme replacement therapy for lysosomal storage disease (LSD) type and Ciba Geigy (the company that would later become Novartis). 1 Gaucher. Three years later, its second-generation product, Cerezyme Genentech passed. Ciba Geigy, however, began working with Tanox (imiglucerase for injection), was also cleared for commercialization. The on anti-IgE antibodies for allergic diseases. lack of treatments for lysosomal storage diseases and effective patient out- Yet Genentech clearly had interest in the area, because it began its own reach and marketing meant that Genzyme could command soaring prices anti-IgE program a few years later—a move that prompted a misappro- for its orphan treatments. In 2000, the two drugs alone provided 66% of priation suit from Tanox. The companies fought in court for three years Genzyme’s entire product revenue. before Genentech, Tanox and Novartis reached a settlement and entered At this time, Novazyme Pharmaceuticals was a young company devel- a cross-licensing agreement for anti-IgE antibodies.
    [Show full text]
  • Genentech 2002 Annual Report the Acceleration of Scientific Knowledge Over Time Has Been Profound— and It Is Ceaseless
    What we don’t yet know could change everything. Genentech 2002 Annual Report The acceleration of scientific knowledge over time has been profound— and it is ceaseless. Today, the span of time between great discoveries in medicine gets smaller and smaller due in part to the relatively new field of biotechnology. And the number of breakthroughs and new approaches to disease continues to grow. At Genentech, we believe we have only just begun to scratch the surface of biotechnology’s potential. Without a doubt, future discoveries will dramatically change our understanding of serious illnesses and potential treatments. Even more importantly, science is likely to create dramatic change at a more personal level— increasing the length and quality of life for our loved ones and ourselves. What if one day everyone could survive cancer? Cancer is the second leading cause of death in the United States behind heart disease, with over 1.2 million new cases diagnosed per year. Some predict it will become number one in the next 10 years. Curing cancer is our ultimate goal, but if we are able to keep cancer in check, extend patients’ lives and improve their quality of life, that will be a major victory over the disease. Genentech developed the first two therapeutic antibodies for cancer in the United States, Rituxan® (Rituximab), which was co-developed with IDEC Pharmaceuticals, and Herceptin® (Trastuzumab) — both of which attack malignant cells without causing extensive damage to healthy tissues. Rituxan and Herceptin are different from chemotherapy in that, although they are serious medicines, they tend to have relatively few side effects and can sometimes be taken for prolonged periods to stave off the disease.
    [Show full text]
  • The WCBP CMC Strategy Forum
    Welcome to the WCBP CMC Strategy Forum We are pleased to welcome you to the WCBP CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The meetings focus on relevant CMC issues throughout the lifecycle of a product and thereby foster collaborative technical and regulatory interactions. The Forum strives to share information with the regulatory agencies to assist them in merging good scientific and regulatory practices. Outcomes of the Forum meetings are published in an appropriate peer-reviewed journal. Each meeting will focus on a CMC related issue such as product characterization, comparability, specifications, etc. The format of each meeting will consist of case studies and presentations by Industry and/or FDA experts to introduce the topic and the key issues of concern. Breakout sessions will then be conducted to allow for additional discussion on the technical and regulatory details of the topics. It is envisioned that the final outcome of the workshop discussions will be the development of a document to be submitted to the appropriate Regulatory Agency designees for their consideration in developing and/or clarifying good regulatory practice guidelines for biotechnology derived products. The success of the CMC Strategy Forum will depend on your active participation in discussing and raising issues pertaining to development of biologics. We encourage you to participate wholeheartedly in the workshops that have been designed to stimulate exchange of ideas and information. We would like to thank the speakers who are giving generously of their time and resources, and to you, for your attendance.
    [Show full text]
  • Taking the Pulse of Biotech
    A Conversation with Nancy Chang OnTheRecord Taking the Pulse of Biotech Biotechnology is risky business. For every start-up that succeeds, between 15 and 20 fail. for HIV, just to prepare the materials alone cost $50,000 per patient, not counting our Houston Branch board member Nancy Chang beat the odds with Tanox Inc., a 20-year-old costs or our time. biotech company that has agreed to be acquired by industry behemoth Genentech Inc. When Tanox first started, I put every- thing I had into the company. We didn’t pay ourselves salaries; the company’s first tele- Q: With such a high failure rate, are biotechs phone system was built on borrowed mon- at risk of extinction? ey. But we did what we had to do to make progress, to grow the company, and these A: Just the opposite. Pharmaceutical compa- were gutsy, risky moves. nies are realizing that it’s so expensive to discover new drugs that they’re relying more Q: How has globalization changed the and more on biotechs for the discovery, de- pharmaceutical industry? velopment and concept phases. Look at it as Big Pharma relying on the little guy. This A: Every biotech company that starts out to- way, they don’t have to pay for the failures. day is global by necessity. You have to learn Eventually, they partner with the smaller how to do business all over the world, to do biotechs that do pass muster. research and development work outside the U.S., to have partnerships with international Q: You came to the U.S.
    [Show full text]